There are currently 238 clinical trials in Tacoma, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including Madigan Army Medical Center, Northwest Medical Specialties PLLC, CCOP - Northwest and Franciscan Research Center-Northwest Medical Plaza. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/27/2024
Locations: Mary Bridge Children's Hospital and Health Center, Tacoma, Washington +1 locations
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071
Recruiting
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
04/27/2024
Locations: Mary Bridge Children's Hospital and Health Center, Tacoma, Washington
Conditions: Anaplastic Astrocytoma, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, Anaplastic Astrocytoma, Not Otherwise Specified
Register for Updates
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634
Recruiting
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Northwest Medical Specialties, PLLC ( Site 5025), Tacoma, Washington
Conditions: Carcinoma, Hepatocellular, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma, Biliary Tract Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
All
Ages:
All
Trial Updated:
04/26/2024
Locations: Local Institution - 01055, Tacoma, Washington
Conditions: Neoplasms
Register for Updates
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
NCT05254834
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: Northwest Medical Specialties (QCCA), Tacoma, Washington
Conditions: Cancer
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Tacoma, Washington
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
NCT06142383
Recruiting
This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Universal Research Group LLC Suite 202, Tacoma, Washington
Conditions: Heart Failure
Register for Updates
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Tacoma, Washington
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT05232929
Recruiting
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study,... Read More
Gender:
All
Ages:
All
Trial Updated:
04/25/2024
Locations: MultiCare Health System Institute for Research and Innovation, Tacoma, Washington
Conditions: Spinal Muscular Atrophy
Register for Updates
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151
Recruiting
This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that lenvatinib + pemb... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: MultiCare Health System-MultiCare Oncology - Puget Sound ( Site 1609), Tacoma, Washington
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204
Recruiting
The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H2): Concurrent chemoradiation therapy with pem... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Multicare Institute For Research And Innovation ( Site 0108), Tacoma, Washington
Conditions: Small Cell Lung Cancer
Register for Updates
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
NCT05298423
Recruiting
This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to cCRT followed by durvalumab with respect to the following... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: MultiCare Health System ( Site 2817), Tacoma, Washington
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates